Alendronate for the treatment of osteoporosis in men

Eric Orwoll, Mark Ettinger, Stuart Weiss, Paul Miller, David Kendler, John Graham, Silvano Adami, Kurt Weber, Roman Lorenc, Peter Pietschmann, Kristel Vandormael, Antonio Lombardi

Research output: Contribution to journalArticle

784 Scopus citations


Background. Despite its association with disability, death, and increased medical costs, osteoporosis in men has been relatively neglected as a subject of study. There have been no large, controlled trials of treatment in men. Methods. In a two-year double-blind trial, we studied the effect of 10 mg of alendronate or placebo, given daily, on bone mineral density in 241 men (age, 31 to 87 years; mean, 63) with osteoporosis. Approximately one third had low serum free testosterone concentrations at base line; the rest had normal concentrations. Men with other secondary causes of osteoporosis were excluded. All the men received calcium and vitamin D supplements. The main outcome measures were the percent changes in lumbar-spine, hip, and total-body bone mineral density. Results. The men who received alendronate had a mean (±SE) increase in bone mineral density of 7.1±0.3 percent at the lumbar spine, 2.5±0.4 percent at the femoral neck, and 2.0±0.2 percent for the total body (P

Original languageEnglish (US)
Pages (from-to)604-610
Number of pages7
JournalNew England Journal of Medicine
Issue number9
Publication statusPublished - Aug 31 2000


ASJC Scopus subject areas

  • Medicine(all)

Cite this

Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., ... Lombardi, A. (2000). Alendronate for the treatment of osteoporosis in men. New England Journal of Medicine, 343(9), 604-610.